Cutting-edge noninvasive detection.
To increase testing compliance by decreasing discomfort.
Currently, there is no immediate diagnosis or combined diagnosis-treatment option for gynecologic malignancies such as cervical, ovarian, and endometrial cancers. This leaves patients vulnerable to greater health risks, including infertility, and the potential of other aggressive types of side effects or risks to quality of life. On a yearly basis there are 7.2 million new cases of cancer of the female reproductive system, of which up to 266,000 result in deaths for cervical cancer.
A microneedle mediated diagnostic patch that detects early onset of cervical cancer, replacing invasive procedures such as the Pap Smear and colposcopies. The digitized medical device, is able to detect novel targets within 30-45 min. - equivalent to a clinical visit. Providing benefits to health professionals for better management of guidelines and improved patient outcomes.
CurivaTM is committed to reducing the incidence of cervical cancer by increasing testing compliance through a non-invasive diagnostic patch. Our patient-centric products deliver accurate, same-day results while reducing diagnostic costs for healthcare providers.
David Advisory Group
Clinical Research Advisor
Vice Chair for Research, Department of Obstetrics and Gynecology
Wayne State University
*Considering additional advisors
GIL MOR, MD PHD
Atlas Venture Labs
Human Capital Advisor
Meet the Curiva team!
diapatch™ screens and detects —
CIN II biomarkers
CIN III biomarkers
Seamless and effortless integration into busy, modern lifestyles, allowing for streamlined, higher quality patient care during the usual women wellness visit or consult with family medicine practitioner, gynecologist, or gynecologic oncologist.